ClinicalTrials.gg
Active, not recruitingNCT06672900Updated Feb 3, 2025

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

A Phase 1 interventional study of Carbamazepine and Itraconazole (Sporanox) in Healthy Volunteer, sponsored by Aligos Therapeutics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs).

In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period.

In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period.

The 2 parts may be conducted in parallel.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ALG-000184
03

In context

Lead sponsor

Aligos Therapeutics is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 and 55 years of age.
  2. 18.0 to 32.0 kg/m\^2
  3. Female participants must have a negative serum pregnancy test at screening.
  4. Subjects must have a 12-lead (ECG) that meets the protocol criteria.

Exclusion criteria

Exclusion Criteria for All Participants:

  1. Participants with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation.
  2. Participants with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc.
  3. Participants with a history of drug allergy.
  4. Participants with excessive use of alcohol defined as regular consumption of ≥14 standard drinks/week (US CDC 2022)
  5. Participants that are unwilling to abstain from alcohol use for 1 week prior to start of the study through end of study follow up.
  6. Participants with positive results for urine drug screen, alcohol or cotinine test at screening and Day -1.
  7. Participants with Hepatitis A, B, C, E or -1/HIV-2 infection or acute infections such as SARS- CoV-2 infection.
  8. Participants with sensitivity to or P-gp substrates, inhibitors/inducers.
  9. Participants with clinically significant abnormal vital signs or physical examination.
  10. Participants with renal dysfunction (e.g., estimated \<90 mL/min/1.73 m\^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration [] formula)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ALG-000184

    Single or multiple doses of ALG-000184, an investigational HBV capsid assembly modulator

    Drug: ALG-000184

  • Experimental
    Carbamazepine

    Multiple doses of carbamazepine, a strong CYP3A4 inducer, to evaluate potential drug-drug interactions with ALG-000184

    Drug: Carbamazepine · Drug: ALG-000184

  • Experimental
    Itraconazole

    Multiple doses of itraconazole, a strong CYP3A4 inhibitor, to evaluate potential drug-drug interactions with ALG-000184.

    Drug: Itraconazole (Sporanox) · Drug: ALG-000184

Interventions

  • DrugCarbamazepine

    Commercially available supply.

  • DrugItraconazole (Sporanox)

    Commercially available supply.

  • Study Investigational Product

06

What researchers measure

Primary outcomes

  1. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of itraconazole (Part 1)

    Time frame: Up to 24 days

  2. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days.

  3. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days

  4. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Itraconazole (Part 1)

    Time frame: Up to 24 days

  5. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days

  6. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Itraconazole (Part 1)

    Time frame: Up to 24 days

  7. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of itraconazole (Part 1)

    Time frame: Up to 24 days

  8. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days

  9. C0 [predose]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of itraconazole (Part 1)

    Time frame: Up to 24 days

  10. C0 [predose]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days

  11. Half-life [t1/2]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of itraconazole (Part 1)

    Time frame: Up to 24 days

  12. Half-life [t1/2]

    Pharmacokinetic parameters of ALG-001075 and metabolite ALG-000302 after multiple doses of Carbamazepine (Part 2)

    Time frame: Up to 29 days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The number and severity of treatment emergent adverse events in up to n=24 participants as assessed by DAIDS v2.1(July 2017)

    Time frame: Up to 24 days for Part 1

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The number and severity of treatment emergent adverse events in up to n=24 participants as assessed by DAIDS v2.1(July 2017)

    Time frame: Up to 29 days for Part 2

  3. Mean Change from Baseline QTc at different exposure levels

    Evaluate the concentration-QT relationship of ALG-000175 and metabolite ALG-000302 to determine the QTc prolongation potential of ALG-000184.

    Time frame: Up to 24 days for Part 1.

  4. Mean Change from Baseline QTc at different exposure levels

    Evaluate the concentration-QT relationship of ALG-000175 and metabolite ALG-000302 to determine the QTc prolongation potential of ALG-000184.

    Time frame: Up to 29 days for Part 2.

Other outcomes

  1. Cholesterol

    Intends to monitor plasma samples from baseline to measure 4-β-hydroxycholesterol, an induction marker of CYP450.

    Time frame: Up to 24 days in Part 1

  2. Cholesterol

    Intends to monitor plasma samples from baseline to measure 4-β-hydroxycholesterol, an induction marker of CYP450.

    Time frame: Up to 29 days in Part 2

  3. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of Carbamazepine and applicable metabolite

    Time frame: 29 days

  4. Area under the concentration time curve [AUC]

    Pharmacokinetic parameters of itraconazole and applicable metabolite

    Time frame: 24 days

  5. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of Itraconazole and applicable metabolite

    Time frame: 24 days

  6. Maximum plasma concentration [Cmax]

    Pharmacokinetic parameters of Carbamazepine and applicable metabolite

    Time frame: 29 days

  7. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of Itraconazole and applicable metabolite

    Time frame: 24 days

  8. Minimum plasma concentration [Cmin]

    Pharmacokinetic parameters of Carbamazepine and applicable metabolite

    Time frame: 29 days

  9. C0 [predose]

    Pharmacokinetic parameters of Itraconazole and applicable metabolite

    Time frame: 24 days

  10. C0 [predose]

    Pharmacokinetic parameters of Carbamazepine and applicable metabolite

    Time frame: 29 days

  11. Half-life [t1/2]

    Pharmacokinetic parameters of Itraconazole and applicable metabolite

    Time frame: 24 days

  12. Half-life [t1/2]

    Pharmacokinetic parameters of Carbamazepine and applicable metabolite

    Time frame: 29 days

  13. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of Itraconazole and applicable metabolite

    Time frame: 24 Days

  14. Time to maximum plasma concentration [Tmax]

    Pharmacokinetic parameters of carbamazepine and applicable metabolite

    Time frame: 29 days

07

Study locations

1 site
  • PPD Austin Research Unit
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Nov 4, 2024
StartActual
Jan 9, 2025
Primary completionEst.
Jul 7, 2025
CompletionEst.
Jul 7, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672900
Lead sponsor
Aligos Therapeutics
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Jan 9, 2025
Primary completion
Jul 7, 2025 (estimated)
Completion
Jul 7, 2025 (estimated)
Last update
Feb 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pevifoscorvir sodium

Start the discussion